yk012
mAbexperimentalBi-specific
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 9, 2023 (NCT06565689)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07234474 | Phase 1 | Feb 28, 2026 | Excyte Biopharma Ltd, Peking University |
| NCT07010835 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2025 | Excyte Biopharma Ltd |
| NCT06982729 | Phase 1 | Mar 8, 2025 | Excyte Biopharma Ltd, Peking University |
| NCT06580301 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2024 | Excyte Biopharma Ltd, Zhejiang University |
| NCT06565689 | Phase 1 | May 9, 2023 | Chinese Academy of Medical Sciences, Excyte Biopharma Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Excyte Biopharma Ltd | For profit | 5 | 5 | 2 | 2023 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1